Aquestive Therapeutics Inc (NAS:AQST)
$ 3.27 0.18 (5.83%) Market Cap: 297.70 Mil Enterprise Value: 220.59 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 57/100

Q4 2018 Aquestive Therapeutics Inc Earnings Call Transcript

Mar 14, 2019 / 12:00PM GMT
Release Date Price: $6.37 (-15.96%)
Operator

Good morning, and welcome to the Aquestive Therapeutics Year-End 2018 Conference Call. (Operator Instructions) As a reminder, this call is being recorded. I would now like to introduce your host for today's conference, Ms. Lauren Walrath, Head, Corporate Marketing and Communications. You may begin.

Lauren Walrath

Thank you, operator. Good morning, and welcome to today's call to review Aquestive Therapeutics' results for the year-ended December 31, 2018. On today's call, I am joined by Keith Kendall, Chief Executive Officer; Ken Marshall, Chief Commercial Officer; Dan Barber, Chief Strategy and Development Officer; and John Maxwell, Chief Financial Officer.

Keith will begin by providing an overview of business developments and context for what lies ahead. Next, Ken will discuss the progress of our commercial activities and the SYMPAZAN launch. Dan Barber will provide us with a review of clinical and regulatory developments related to Aquestive's proprietary pipeline. And finally, John will review the company's financial results for the fourth quarter and full

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot